Ohio Court Weighs FCA Constitutionality in TriHealth Case

Every so often, a case comes along that is about much more than the fight in front of the judge. The TriHealth False Claims Act battle is one of those cases. On the surface, it is a health care fraud dispute involving allegations that physician compensation and referral arrangements ran afoul of federal law. Underneath that surface, though, sits a much bigger question: can private whistleblowers, acting in the government’s name, keep bringing False Claims Act cases at all if the statute’s qui tam machinery is unconstitutional?

That is the pressure point in the TriHealth litigation out of the Southern District of Ohio. The court did not blow up the False Claims Act. Far from it. Judge Douglas Cole rejected the constitutional challenge and allowed the case to proceed. But he also did something important: he acknowledged that the issue is serious enough, live enough, and expensive enough to justify early appellate attention. In legal terms, he said the question was big. In normal-person terms, he said this was not the kind of argument to leave marinating in the slow cooker for three more years while everyone spends a fortune on discovery.

The result is a case that has become a useful lens for understanding the current constitutional fight over the FCA. For hospitals, physician groups, compliance officers, relators, and defense counsel, TriHealth is not just another motion-to-dismiss ruling. It is a snapshot of where the law stands, where the pressure is building, and why the eventual showdown may land at the U.S. Supreme Court with all the subtlety of a dropped piano.

What the TriHealth Case Is Actually About

The underlying allegations come from two relators. One is Timothy Murphy, a former Physician Practices Chief Financial Officer for TriHealth. The other is Dr. Set Shahbabian, a former TriHealth neurosurgeon who later filed a separate but similar qui tam suit. Their claims center on alleged physician compensation arrangements that supposedly rewarded referrals and shifted financial losses in ways that implicate the Stark Law and the Anti-Kickback Statute. Once those laws are in the mix, the False Claims Act usually is not far behind, because claims for federal reimbursement can become “false” if they are tied to unlawful referral schemes or false certifications of compliance.

That part matters because the FCA is the federal government’s heavyweight anti-fraud statute. It allows the government to recover treble damages and civil penalties from parties that knowingly submit false claims for federal money. It also allows private whistleblowers, known as relators, to sue on the government’s behalf and share in any recovery. In health care, where Medicare and Medicaid billing touch everything from hospital systems to physician practices to vendor contracts, the FCA is not just another regulatory tool. It is the regulatory tool that keeps chief compliance officers awake at 2:13 a.m., staring at the ceiling and rethinking every compensation spreadsheet they have ever loved.

Importantly, the TriHealth decisions came at the pleading stage. That means the court was deciding whether the complaints could move forward, not whether the defendants were liable. The allegations remain allegations. But the constitutional attack made the case especially significant because TriHealth and related defendants argued that the structure of the FCA itself is defective when private relators press these suits without enough executive-branch control.

Why the Constitutionality Question Is Suddenly So Hot

For decades, the False Claims Act’s qui tam system survived constitutional attacks. Courts generally treated relators as unusual but permissible enforcers of public rights, in part because the government retains meaningful control. The complaint is filed under seal. The government gets the first look. It can intervene. It can monitor the case. And under the Supreme Court’s decision in Polansky, the government can intervene later and seek dismissal, reinforcing the idea that the United States remains the real party in interest.

But the mood changed when several justices began openly signaling concern about Article II. The Appointments Clause requires officers of the United States to be appointed through constitutional channels, not by the legal equivalent of “I picked myself, thanks.” The Take Care Clause assigns the President responsibility to ensure the laws are faithfully executed. Critics of qui tam litigation argue that relators exercise executive power without proper appointment and without enough presidential supervision, especially in declined cases where the government sits out and the relator drives the bus.

That argument gained fresh oxygen after the Florida district court’s decision in Zafirov, which concluded that the FCA’s qui tam provisions are unconstitutional under Article II. Whether Zafirov ultimately sticks is another question. But its existence changed the conversation. Suddenly, defendants across the country had a shiny new opinion to wave around, several Supreme Court writings had sprinkled constitutional breadcrumbs into the record, and judges who might once have treated the issue as settled began saying, in effect, “Well, settled-ish.”

What the Ohio Federal Court Decided

In July 2025, Judge Cole denied TriHealth’s motions to dismiss in Murphy’s case and reached the same core constitutional result in the related Shahbabian litigation. On Article III standing, the court said the defendants were out of luck because the Supreme Court in Vermont Agency of Natural Resources v. Stevens already recognized that a relator has standing to pursue an FCA suit on behalf of the United States. That point, for the Ohio court, was not a fresh frontier. It was already spoken for.

On Article II, the court held that binding Sixth Circuit precedent controlled the day. The key case was United States ex rel. Taxpayers Against Fraud v. General Electric Co., where the Sixth Circuit held that FCA relators are not “officers” within the meaning of the Appointments Clause and that the Executive Branch retains sufficient control over the relator’s conduct to satisfy the Take Care Clause. Judge Cole made clear that, whatever a court might think as a matter of first impression, a district judge in the Sixth Circuit does not get to freestyle past controlling precedent just because newer arguments sound fashionable in constitutional circles.

That reasoning is a reminder of how lower courts actually function. They do not get to swap out binding circuit law every time a dissent gets spicy or another district judge across the country writes a bold opinion. The TriHealth defendants leaned on recent Supreme Court separation-of-powers decisions, Justice Thomas’s dissent in Polansky, and the Florida ruling in Zafirov. Judge Cole essentially said: interesting, important, definitely not nothingbut still not enough to let a district court ignore controlling Sixth Circuit authority.

Why the Court Certified an Interlocutory Appeal Anyway

Here is where the TriHealth ruling gets especially interesting. Even though the court rejected the constitutional challenge, it certified the Article II question for interlocutory appeal under 28 U.S.C. § 1292(b). That is a procedure reserved for controlling legal questions where there is substantial ground for difference of opinion and where immediate review could materially advance the end of the case.

Judge Cole found those standards satisfied on the Article II issue. Why? Because if the FCA’s qui tam provisions are unconstitutional, the case likely cannot continue in its current posture. That makes the question controlling. And because FCA litigation is discovery-heavy, document-heavy, expert-heavy, and invoice-heavy, an early answer could save enormous resources. Nobody wants to spend years digging through compensation models, board decks, reimbursement data, and physician contracts only to discover the entire suit was riding on a constitutional sled with one ski missing.

The court also pointed to the existence of serious disagreement. Zafirov had already held the statute unconstitutional. Supreme Court justices had flagged the issue. And the Supreme Court in Stevens expressly reserved the Article II question rather than resolving it. So while the Ohio court believed it was bound to reject the challenge, it also recognized that reasonable jurists could disagree about whether older circuit precedent would survive fresh scrutiny higher up the ladder.

What the Sixth Circuit Did Next

When the case reached the Sixth Circuit on petitions for permission to appeal, the appellate court denied them in January 2026. That order mattered because it showed the court was not ready to reopen the question on an interlocutory basis. The panel concluded that, even if the issue was important, there was not a substantial ground for difference of opinion within the Sixth Circuit because Taxpayers Against Fraud remained controlling circuit precedent.

That is a subtle but important point. The Sixth Circuit did not issue a sweeping new merits opinion reanalyzing Article II from scratch. Instead, it effectively said that the old rule is still the rule here, and that is enough to defeat interlocutory review. So for now, within the Sixth Circuit, the qui tam provisions remain standing on their own two statutory feet.

Still, the constitutional cloud did not vanish. It just drifted to another part of the sky. Other courts are continuing to wrestle with the issue, especially in light of Zafirov and the Supreme Court’s recent signals. So TriHealth did not end the debate. It clarified the current position in the Sixth Circuit while underscoring that the national fight is very much alive.

Why This Matters Beyond TriHealth

The stakes here are enormous because the FCA is not some dusty museum statute brought out for special occasions. It is one of the federal government’s most productive fraud-enforcement tools. The Department of Justice reported more than $6.8 billion in FCA settlements and judgments in fiscal year 2025, the highest annual total on record, with health care matters accounting for more than $5.7 billion. Whistleblowers filed 1,297 qui tam suits that year alone.

Those numbers explain why constitutionality arguments have become so consequential. If courts were to hold that relators cannot constitutionally prosecute non-intervened FCA cases, the practical effect could be enormous. The government would likely retain authority to pursue fraud cases itself. But the pipeline of relator-driven litigation would narrow sharply, especially in sectors like health care where insiders often provide the road map.

For providers, that could mean fewer opportunistic suits but also more uncertainty during the transition. For relators, it could mean the value of coming forward changes dramatically. For the DOJ, it could mean increased pressure to intervene more often, dismiss more aggressively, or rethink how it deploys resources. And for compliance teams, the headline is simple: do not mistake a constitutional debate for a compliance holiday. The Stark Law and Anti-Kickback Statute do not stop mattering because lawyers are arguing about the separation of powers.

The Real Legal Tension at the Center of the Case

What makes TriHealth so fascinating is that both sides are arguing from principles that have real force. Defendants say the Executive Branch cannot outsource federal litigation power to self-appointed private actors and still call that arrangement constitutionally tidy. Relators and the government answer that the FCA contains enough controls, enough historical pedigree, and enough continuing government authority to keep the structure valid.

That tension is why courts keep circling back to control. How much authority does a relator actually exercise? How much oversight does the government really have in a declined case? Is history enough to validate a modern qui tam regime that operates at today’s scale and financial intensity? And if the government can intervene later, restrict the relator, or seek dismissal, does that preserve executive accountability or merely tidy up the optics?

The Ohio court answered those questions the way Sixth Circuit precedent required: the controls are sufficient, the relator is not an officer, and Article III standing exists. But the court also practically invited higher courts to take another look. That is the genius of TriHealth as a story. It is both conservative and combustible at the same time. The district court followed precedent faithfully while practically hanging a sign in the window that says, “This issue is still coming back, probably with friends.”

Experience on the Ground: What This Kind of Case Feels Like in Real Life

To understand the TriHealth fight, it helps to think about how these cases are actually lived, not just how they are captioned. For a relator, an FCA case often begins less like a grand constitutional crusade and more like a long, lonely season of saying, “This does not look right,” while everyone else in the room suddenly discovers deep affection for silence. In health care organizations, compensation structures are dense, spreadsheets are revered, and referral patterns can be explained with the sort of confidence usually reserved for astrology. A whistleblower who pushes back on those arrangements may feel like the only person in the building reading the footnotes.

For in-house counsel and compliance teams, a case like TriHealth is rarely just about one allegation. It becomes a stress test of systems. How were physician deals documented? Who reviewed fair-market-value assumptions? Was anyone monitoring loss subsidies, management fees, referral volume, or certification language on claims and cost reports? A constitutional challenge to the FCA can look tempting in that setting because it offers the possibility of a front-end escape hatch. If the qui tam suit itself is structurally flawed, maybe the company avoids years of litigation. That is a very appealing sentence when discovery has started breeding in the dark.

For defense lawyers, the experience is strategic whiplash. On one hand, you still must litigate the old-fashioned way: attack falsity, scienter, causation, materiality, pleading standards, and damages. On the other hand, you now also have to decide whether to push the bigger Article II argument, knowing it may not win today but could preserve something valuable for tomorrow. That is the TriHealth lesson in miniature. Even losing the constitutional motion can shape the next move, frame the appeal, and buy time through a stay.

And for judges, these disputes are not abstract theory seminars. They are case-management headaches with constitutional frosting. FCA cases are expensive. Health care records are massive. The number of people, contracts, coding practices, and reimbursement pathways involved can turn a case file into a small continent. So when a credible argument arises that the litigation might be structurally invalid, courts have to balance fidelity to precedent with practical judgment. That is exactly what happened in Ohio. Judge Cole followed binding law, but he also recognized the real-world burden of forcing everyone to plow through years of discovery while a potentially dispositive constitutional issue sat unresolved.

In that sense, TriHealth captures the lived experience of modern FCA litigation perfectly. It is technical, high stakes, deeply procedural, and oddly human. It involves statutes written to protect public money, private insiders who claim they saw something rotten, defendants who say the legal mechanism itself is broken, and courts trying to decide not just who should win, but who is even allowed to fight. That is why the case matters. It is not merely about TriHealth. It is about how a major anti-fraud system works when everyone suddenly starts asking whether the wiring behind the walls was constitutional all along.

Conclusion

The TriHealth case shows that the False Claims Act’s constitutional debate has moved from academic side chatter to headline litigation strategy. The Southern District of Ohio held the line, relying on existing Sixth Circuit precedent to reject the Article II challenge and to confirm Article III standing. The Sixth Circuit then declined interlocutory review, signaling that, at least in that circuit, old precedent still carries real weight.

But the bigger story is not over. TriHealth illustrates how lower courts are navigating a legal landscape in which the FCA remains hugely important, whistleblower suits continue to drive enforcement, and constitutional objections are becoming harder to shrug off with a casual judicial hand wave. For now, the statute survives in the Sixth Circuit. Yet the very fact that courts are taking the issue seriously enough to certify appeals, stay cases, and parse Supreme Court signals tells you everything you need to know: the next chapter is not a matter of if, but when.

In other words, the FCA is still very much alive. It is just also being asked to produce its constitutional ID at the door.